In its two lead cancer assets, STP705 and STP707, Sirnaomics is using the technology to deliver two siRNA oligonucleotides to knock down TGF-β1 and COX-2 gene expression. TGF-β1 and COX-2 are ...

Since the clinical development of siRNA cancer therapeutics is limited by the poor interstitial transport and inefficient transfection in solid tumors, we explored the possibility of using tumor ...

This approach was successful in preclinical models, holding promise for suppressing tumor growth in patients. We hypothesized that using mRNA and siRNA simultaneously could restore tumor ...

Meanwhile, oxygen produced by cyanobacteria through photosynthesis enhances the tumor microenvironment, promoting the efficacy of siRNA delivery and the reprogramming of TAMs. Experimental results ...

40)–siRNA Cell cycle proteins PLK1 (yes) Intrahepatic mouse tumor models and s.c. tumor models [78–80] DSPC:Chol:PEG–C–DMA:cationic lipid (10:40:10:40)–siRNA Factor VII (yes) C57BL/6 mic ...